Proliferating Cell Nuclear Antigen (PCNA)

Subscribe to Selected New Research on Proliferating Cell Nuclear Antigen

3767 relevant articles (85 outcomes, 559 trials/studies) found for this Bio-Agent

Description: Nuclear antigen with a role in DNA synthesis, DNA repair, and cell cycle progression. PCNA is required for the coordinated synthesis of both leading and lagging strands at the replication fork during DNA replication. PCNA expression correlates with the proliferation activity of several malignant and non-malignant cell types.

Also Known As:

PCNA; PCNA-Cyclin; PCNA Cyclin; Antigen, Proliferating Cell Nuclear

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins

Proteins: 58433

Nuclear Proteins: 1357

Proliferating Cell Nuclear Antigen: 3767

p27 antigen: 12

proliferating cell nuclear antigen p145: 2

Biological Factors: 931

Antigens: 95584

Nuclear Antigens: 407

Proliferating Cell Nuclear Antigen: 3767

p27 antigen: 12

proliferating cell nuclear antigen p145: 2

Biological Markers: 21607

Biological Tumor Markers: 3444

Proliferating Cell Nuclear Antigen: 3767

p27 antigen: 12

proliferating cell nuclear antigen p145: 2

Experts

1.	Yue, Hui: 4 articles (08/2005 - 02/2003)
2.	Alexandrakis, M G: 3 articles (02/2007 - 01/2004)
3.	Minimo, Corrado: 3 articles (05/2006 - 05/2004)
4.	Giordano, Antonio: 3 articles (05/2006 - 05/2004)
5.	Claudio, Pier Paolo: 3 articles (05/2006 - 05/2004)
6.	Lu, Gongcheng: 3 articles (12/2003 - 01/2002)
7.	Zeng, Fuqing: 3 articles (12/2003 - 01/2002)
8.	Feng, Xin-Li: 3 articles (07/2003 - 02/2003)
9.	Song, Fu-Lin: 3 articles (07/2003 - 02/2003)
10.	Matturri, L: 3 articles (07/2001 - 05/2000)

Related Diseases

1.	Neoplasms (Cancer) 12/15/2004 - "MCM3 antibody was the most specific for multiple human cancers, whereas proliferating cell nuclear antigen was relatively less effective in specificity, and Ki-67 failed to detect several human cancers. " 09/01/1997 - "When patients with compromised skull and/or cranial nerves (T4 tumors), who had a very short survival, were eliminated from the analysis, only the mitotic index and proliferating cell nuclear antigen allowed discrimination of a subset of patients with poor prognoses. " 03/01/2005 - "Treated tumors showed a threefold smaller volume (P < 0.025) and a significant reduction of the mitotic index and of PCNA expression. " 06/01/2002 - "Tumor growth and cytokine levels in plasma and the liver were compared between rats that underwent MCT and rats that did not.RESULTS: The mean tumor weight in the MCT group (222.6+/-51.5 mg, mean+/-SD) was significantly greater than that in the control group (126.7+/-19.7 mg, P<0.01) at postoperative day (POD) 5. Immunohistochemistry for anti-proliferating cell nuclear antigen showed the labeling index in the MCT group (90.4%) to be higher than that in the control group (76.7%, P<0.01). " 09/01/1999 - "PCNA and Ki-67 expressions showed significant differences between non-recurring and recurring groups and more variability in stage II than in stage I. Recurrence rates according to tumor size were 0% for </=2.5 cm, 4% for 2.5 to 5.0 cm, and 55.8% for >/=5.0 cm. It was concluded that PCNA and Ki-67 expression profiles were considered to be closely related to tumor stage and showed some promise for predicting the disease recurrence." Order ALL the reference details at left...
2.	Carcinoma (Carcinomatosis) 04/01/2005 - "CONCLUSION: In this study PCNA proved to be an independent prognostic indicator in predicting disease-free and overall survival in breast carcinoma patients." 03/01/1999 - "METHODS: Hp was examined in 70 patients with gastric carcinoma, 62 patients with pre-malignant lesions and 16 controls by improved Warthin-Starry method and PCNA, p53, cerbB-2 protein examined immunohistochemically. " 07/01/2008 - "[Study of gastric carcinoma and PCNA and c-met gene abnormality]" 07/01/2005 - "[Study on expression and relationship between proliferating cell nuclear antigen and p53 oncoprotein in nasopharyngeal carcinoma]" 07/01/2002 - "[The study of expression of proliferating cell nuclear antigen and its gene in hypopharyngeal carcinoma]" Order ALL the reference details at left...
3.	Neoplasm Metastasis (Metastasis) 06/01/2009 - "A multivariate analysis identified two independent factors that significantly affected both disease-free and overall survival: lymph node metastasis and PCNA index. " 04/15/1996 - "Three variables including deep invasion, liver metastasis, and advanced stages were significantly greater for patients with high PCNA LI ( > 49.4%) than for patients with low PCNA LI ( < 49.4%). " 04/01/2003 - "In our study, there was some correlation in the grade of PCNA proliferating index(PI) with the clinical stages or cervical lymph node metastasis of NPCs. " 08/01/2001 - "This study showed that p53-negative or low-PCNA index patients have relatively good prognoses despite extensive lymph node metastasis." 01/01/1996 - "As a result of this study, PCNA labeling index was suggested to be effective as one of the predictors of lymph node metastasis." Order ALL the reference details at left...
4.	Adenocarcinoma 08/01/1999 - "The strongly positive results of PCNA staining, regardless of the degree of differentiation, proves that even highly differentiated adenocarcinoma exhibits a high degree of cell activity. " 08/01/1995 - "The PCNA-LI of routinely processed specimens of adenocarcinoma of the gallbladder may be helpful for the evaluation of cell proliferation and prognosis." 04/01/2002 - "The aim of this study was to determine PCNA and Ki-67 expression in locally confined renal adenocarcinoma, their relationship with other histopathological variables and prognostic significance. " 04/01/2002 - "OBJECTIVE: PCNA and Ki-67 expression are used as markers of cellular proliferation and different studies have investigated their value as prognostic indicators for renal adenocarcinoma. " 01/01/1999 - "Additional, larger studies are needed to evaluate the prognostic value of PCNA and p53 expression in endometrial adenocarcinoma." Order ALL the reference details at left...
5.	Squamous Cell Carcinoma (Epidermoid Carcinoma) 03/01/2009 - "In this study, the expressions of Ror2 in the normal mucosa, the epithelium dysplasia, and squamous cell carcinoma (SCC) of the oral cavity were investigated, and possible differences in the expression patterns of Ror2 and of p53, Ki67, or PCNA were examined. " 01/01/2009 - "The present study compared the expression of proliferative (COX-2, Ki67 and PCNA) and angiogenic markers (CD34 and NG2) between preneoplastic bronchial squamous dysplasia lesions and invasive squamous cell carcinoma. " 08/01/2008 - "Expression of PCNA and bcl-2 in basaloid squamous cell carcinoma of the larynx: a controlled study." 11/01/2001 - "[A study on expression of CD44V6 and PCNA in squamous cell carcinomas]" 05/01/2001 - "Basaloid squamous carcinoma of the oral cavity: report of 2 cases and study of AgNOR, PCNA, p53, and MMP expression." Order ALL the reference details at left...

Related Drugs and Biologics

1.	Proliferating Cell Nuclear Antigen (PCNA)
2.	DNA (Deoxyribonucleic Acid)
3.	Antigens
4.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
5.	Caspase 3 (Caspase-3)
6.	Phosphotransferases (Kinase)
7.	Transferases
8.	nucleolar organizer region associated proteins
9.	Cyclin D1
10.	Epidermal Growth Factor Receptor (EGF Receptor)

Related Therapies and Procedures

1.	Transplantation (Transplant Recipients)
2.	Adjuvant Chemotherapy
3.	Vitrectomy
4.	Drug Therapy (Chemotherapy)
5.	Chemoprevention

Best Treatments:
Research Summary Report
on Neoplasms

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 20112 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>